Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Total Non-Current Liabilities (2024 - 2025)

Century Therapeutics (IPSC) has disclosed Total Non-Current Liabilities for 2 consecutive years, with $67.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 63.26% to $67.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $67.6 million, a 63.26% decrease, with the full-year FY2024 number at $183.1 million, changed N/A from a year prior.
  • Total Non-Current Liabilities was $67.6 million for Q3 2025 at Century Therapeutics, up from $66.7 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $183.9 million in Q3 2024 to a low of $66.7 million in Q1 2025.